The detailed data of the Phase 3 clinical trial of Kexing inactivated vaccine is announced, and the protective effect can be observed 14 days after the first dose of the vaccine

▎The content team editor of WuXi AppTec.
Today, the research team led by the Brazilian Butantan Institute published on the preprint website SSRN the inactivated vaccine CoronaVac developed by Beijing Kexing Zhongwei Biotechnology Co.
, Ltd.
(Sinovac) and a number of partners.
, Detailed results of a phase 3 clinical trial conducted among Brazilian medical workers.

The results of this test showed that the protective effect of two doses of CoronaVac on symptomatic COVID-19 reached 50.
7%, and the protective effect of moderate to severe cases and severe COVID-19 reached 100%.

It is worth mentioning that this study also provides a variety of detailed analysis data, including the protective efficacy after a single vaccination, and the neutralizing efficacy of the vaccinated volunteers' serum against a variety of new coronavirus mutant strains.

Let's take a look at the detailed results of this study.